My name is Keun-Yeong Jeong, and I received my Ph.D. from Korea University College of Medicine. I am the CEO/CTO of PearlsInMires. I am developing innovative anticancer drugs that induce therapeutic effects by activating specific targets, moving beyond traditional inhibition methods. My work is driven by the urgent need for more effective cancer treatments and is distinguished by a novel approach that leverages target activation. This unique strategy sets my research apart, offering new hope in the fight against cancer. I hold various anticancer drug patents and peer-reviewed articles subjected to SCI journals. I am committing to advancing cancer research and treatment as an active AACR, ASCO, and KCA member. With a decade of experience and over 1,000 peer reviews, I regularly contribute editorials to the World Journal of Gastrointestinal Oncology. My personal and professional goal is to develop cancer therapies free from toxicity and resistance by regulating ADP-ribose. My long-term research focuses on cancer biology, drug development, and molecular mechanisms. As a CEO managing a diverse team, I excel in active listening, ensuring every voice is heard and valued. My communication skills foster clear and effective dialogue, while my interpersonal skills build strong, collaborative relationships. I demonstrate leadership by inspiring and guiding my team towards shared goals. My mentoring skills help develop talent and nurture growth. With robust management skills, I efficiently oversee operations and drive productivity. My problem-solving abilities enable me to tackle challenges creatively and strategically, ensuring the success and resilience of my organization. I enjoy light walks and reading books regularly.